mk-3118 has been researched along with enfumafungin* in 2 studies
2 other study(ies) available for mk-3118 and enfumafungin
| Article | Year |
|---|---|
Natural Enfumafungin Analogues from
Ibrexafungerp, an inhibitor of fungal β-(1,3)-d-glucan synthase, represents the first new class of antifungals to be approved in the last 20 years. Ibrexafungerp is a semisynthetic derivative of the naturally occurring triterpene glycoside enfumafungin. In order to search for new analogues of enfumafungin and to probe its biosynthesis, we undertook a reinvestigation of Topics: Antifungal Agents; Glycosides; Molecular Docking Simulation; Triterpenes | 2023 |
Differential Activity of the Oral Glucan Synthase Inhibitor SCY-078 against Wild-Type and Echinocandin-Resistant Strains of Candida Species.
SCY-078 (formerly MK-3118) is a novel orally active inhibitor of fungal β-(1,3)-glucan synthase (GS). SCY-078 is a derivative of enfumafungin and is structurally distinct from the echinocandin class of antifungal agents. We evaluated the Topics: Administration, Oral; Antifungal Agents; Candida; Candida glabrata; Candidiasis; Drug Resistance, Fungal; Echinocandins; Glucosyltransferases; Glycosides; Microbial Sensitivity Tests; Mutation; Triterpenes | 2017 |